The latest from Faes Farma


July 1st, 2026

Faes Farma advances its international expansion through an agreement to commercialise a new urology treatment in Latin America


The company has signed an exclusive licensing and supply agreement with Dongkook Pharmaceutical to register and commercialize Uresco in 13 Latin American countries. The agreement includes a total amount of up to […]



More info

June 25th, 2026

Faes Farma holds its Annual General Shareholders’ Meeting following a key year in the execution of its Strategic Plan


Shareholders approved all items on the agenda, including the 2025 annual accounts, as well as the appointment of Jacobo Llanza and Ángel Agudo as members of the Board of Directors. The Meeting […]



More info

April 30th, 2026

Faes Farma exceeds €200 million in revenue (+31%) and increases its net profit by +9% in the first quarter


Revenue grew by +31%, exceeding guidance, driven by the strength of international markets, both in direct sales and licensing, alongside acquisitions. The Pharma business reached €175 million (+31%), with ophthalmology establishing itself […]



More info

All the news